Insider trading disclosures filed this week reveal concentrated buying by corporate leaders and investment groups alongside substantial sell-side activity by other executives. Below is a company-by-company review of the most material filings disclosed on Monday, preserving the exact transaction details reported in the securities filings.
Top insider buys
Alkami Technology, Inc. (NASDAQ: ALKT) - On March 12, 2026, a consortium of investment entities operating under the General Atlantic umbrella acquired 500,000 shares of Alkami Technology common stock at a weighted average price of $18.33 per share, producing total consideration of $9,165,000. The individual trades executed at prices from $18.30 to $18.36. After these purchases, the reporting owners collectively hold 15,379,451 shares of Alkami Technology. The filing lists multiple General Atlantic-related entities as the reporting parties, specifically: General Atlantic GenPar (Bermuda), L.P.; GAP (Bermuda) L.P.; GAP Coinvestments CDA, L.P.; General Atlantic (AL), L.P.; General Atlantic (AL) SPV, L.P.; General Atlantic (SPV) GP, LLC; GA AL Holding, L.P.; General Atlantic Partners (Bermuda) IV, L.P.; and General Atlantic (SPV) GP (Bermuda), LLC. The disclosure notes that ALKT shares have declined roughly 32% over the past six months and are trading at $17.61. The filing also indicates that Alkami was not profitable over the last twelve months, while analysts forecast the company to reach profitability this year; InvestingPro analysis cited in the filing judges the stock to be undervalued at current levels.
Vail Resorts (NASDAQ: MTN) - Robert A. Katz, serving as Chief Executive Officer and Chairperson of the Board, bought 37,500 shares of Vail Resorts common stock on March 16, 2026. The weighted average price paid was $131.81 per share, with individual trade prices ranging from $131.37 to $131.88, bringing the aggregate transaction value to approximately $4.9 million. Following this purchase Katz is reported to directly own 285,312 shares of Vail Resorts. The filing notes that the company’s stock is trading close to its 52-week low of $126.16 and references an InvestingPro assessment that finds the company undervalued on a Fair Value basis. The disclosure also references an InvestingPro tip that management has been actively repurchasing shares.
ContextLogic Holdings Inc (NASDAQ: LOGC) - Director Bobbili Raja reported a series of purchases totaling 71,000 shares of common stock between March 12 and March 16, 2026. The aggregate purchase cost was $585,058, with per-share prices spanning $8.00 to $8.3404. The filing details that on March 12, Raja bought 6,500 shares at $8.00; on March 13, he acquired 35,229 shares at a weighted average of $8.2014 (individual trade prices $8.10 to $8.24); and on March 16, he purchased 29,271 shares at a weighted average price of $8.3404 (with trade prices ranging from $8.20 to $8.50).
Surrozen, Inc. (NASDAQ: SRZN) - TCG Crossover Fund II, L.P., TCG Crossover Fund III, L.P., and affiliated entities disclosed a sequence of acquisitions in Surrozen common stock totaling approximately $1.2 million. The reported purchase prices per share ranged from $24.8769 to $24.9857. The filings enumerate the buys as follows: on March 12, 2026, TCG Crossover Fund II acquired 6,187 shares and TCG Crossover Fund III acquired 6,187 shares; on March 13, Fund II acquired 17,717 shares and Fund III acquired 17,716 shares; and on March 16, Fund II acquired 595 shares and Fund III acquired 595 shares.
Huntington Bancshares Inc (NASDAQ: HBAN) - Stephen Steinour, President, CEO and Chairman, purchased 32,277 shares of Huntington Bancshares common stock on March 12, 2026, at $15.49 per share, for a total consideration of $499,970. The filing accompanies several analyst notes and forecast adjustments for Huntington included in the reporting materials: DA Davidson reduced its price target to $20 from $21 while retaining a Buy rating and cited integration risks tied to recent acquisitions; Truist Securities maintained a Buy rating with a $21 price target but lowered its 2026 EPS estimate from $1.70 to $1.60 and trimmed 2027 EPS to $1.92; Morgan Stanley reaffirmed an Overweight rating and a $21 target while lowering its 2027 EPS range to $1.90-1.93. Those analyst annotations and revisions are included in the materials filed alongside the insider transaction.
Top insider sells
Natera, Inc. (NASDAQ: NTRA) - Matthew Rabinowitz, Executive Chairman, sold 203,520 shares of common stock between March 12 and March 16, 2026, under a prearranged Rule 10b5-1 trading plan. The shares were sold at prices ranging from $186.7494 to $198.0204, yielding aggregate proceeds of roughly $38.3 million. The filing also records that Rabinowitz exercised options to acquire 200,000 shares of Natera common stock at an exercise price of $9.59 per share, for total exercise cost of $1,918,000. The filing notes that Natera shares currently trade at $197.68, representing a 32% gain over the past year but a 14% decline year-to-date.
Vicor Corp (NASDAQ: VICR) - Patrizio Vinciarelli, Chairman and CEO, sold 39,700 shares of Vicor common stock on March 13, 2026. Those sales produced total proceeds of $8,542,807 and were executed at weighted average prices that ranged from $165.2118 to $175.7998 per share, as shown in the Form 4 filing.
Phillips 66 (NYSE: PSX) - Brian Mandell, Executive Vice President, disclosed sales of 42,800 shares of Phillips 66 common stock on March 12, 2026, for approximately $7.2 million. The weighted average price reported was $169.527, with individual trade prices between $169.50 and $169.55. The filing also states that Mandell exercised options to acquire 42,800 shares at an exercise price of $89.57 per share, for total option exercise cost of $3,833,595. The disclosure highlights that Phillips 66 shares were trading near a 52-week high of $178.38 and at $173.48 at the time of the report, following a year-to-date gain of 35.5%; InvestingPro analysis cited in the filing characterizes Phillips 66 as undervalued at current levels, noting a P/E ratio of 16.05 and a PEG of 0.14. The filing indicates that the exercised options were part of an employee stock option plan that vested in three equal annual installments beginning February 4, 2021.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) - Kumar Neil, Chief Executive Officer, through co-trustee trusts, sold 70,185 shares of BridgeBio common stock across March 12 and March 13, 2026, under a prearranged Rule 10b5-1 plan. The transactions generated approximately $5.5 million in proceeds. The filing breaks down the multiple tranches executed on March 12 at prices ranging from $68.4686 to $70.15 per share: 14,337 shares at a weighted average of $68.4808; 5,363 shares at $69.3176; 300 shares at $70.15; 13,885 shares at $68.4686; 5,815 shares at $69.2913; and another tranche of 300 shares at $70.15. The filing notes the stock has risen 115% over the past year and is trading at $71.03; InvestingPro analysis included in the filing places the stock on its Most Undervalued list relative to Fair Value.
United Therapeutics (NASDAQ: UTHR) - Martine Rothblatt, Chairperson and CEO, sold 9,440 shares of common stock on March 13, 2026, for about $5.1 million. The reported sale prices per share range from $535.4265 to $542.035. The filing additionally records that Rothblatt exercised stock options to acquire 9,500 shares at an exercise price of $146.03 per share, for a total exercise cost of $1,387,285.
What the filings show collectively
The set of Form 4 disclosures filed this week details both notable insider accumulation and sizeable disposals. On the buy side, concentrated purchases were flagged for Alkami Technology and Vail Resorts, as well as purchases by a company director at ContextLogic and by investment funds in Surrozen. Huntington’s chief executive also disclosed a nearly $500,000 purchase. On the sell side, executive and chair-level sales totaled multi-million-dollar proceeds at Natera, Vicor, Phillips 66, BridgeBio and United Therapeutics, with some filings also reporting simultaneous option exercises.
Several of the filings reference InvestingPro valuations or analyst commentary included in the submission materials, and a handful disclose company-specific context such as near 52-week lows or highs, recent share-performance trends, analyst rating and estimate changes, option exercise schedules and reported holdings after the trades.
Investor takeaway
Insider purchases are often interpreted as signals of confidence, while insider sales can reflect a range of motives including diversification or personal liquidity needs. The filings presented here include both sizable purchases and large planned sales under Rule 10b5-1 plans as well as option exercises. Investors should treat these disclosures as one input among many when assessing a company's outlook, and should note the specific transaction mechanics and any analyst commentary that accompanied the filings.
Note: This article only reports the transaction details and accompanying notes as disclosed in the filings; it does not provide investment advice.